Item 2.02 Results of Operations and Financial Condition.
OnNovember 10, 2022 ,Oyster Point Pharma, Inc. (the "Company") issued a press release to report the Company's financial results for the quarter endedSeptember 30, 2022 . The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press Release datedNovember 10, 2022 104 Cover Page Interactive Data File
(embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source